MS
Morgan Stanley
MS has the edge over PRK overall, supported by stronger fundamentals and stronger modeled upside.
PRK
Park National Corporation
PRK's outlook is improving, though it still trails on the overall score.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
PRK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
PRK's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like PRK.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
PRK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $145 | -18% |
| Forward | 13x | $176 | — |
| Fair | 15x | $172 | -2.7% |
| Current | 16x | $176 | — |
| Expensive | 17x | $196 | +11% |
Historical ranges are pointers, not guarantees.
PRK has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
PRK Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for PRK, with profitability improving.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over PRK on earnings, with stronger typical year-over-year growth.
PRK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.16 | +16% |
| Q3 2026 | $11.37 | +4.6% |
| Q2 2026 | $11.16 | +8.3% |
| Q1 2026 | $10.90 | +12% |
| Q4 2025 | $11.11 | +19% |
| Q3 2025 | $10.87 | +29% |
| Q2 2025 | $10.30 | +23% |
| Q1 2025 | $9.75 | +23% |
| Q4 2024 | $9.32 | +19% |
PRK's earnings per share have climbed steadily: $11.37 over the past year, up 4.6% from the year before, and higher year over year for nine quarters in a row.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over PRK on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
PRK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $177.4M | +25% |
| Q2 2026 | $178.4M | +26% |
| Q1 2026 | $159.5M | +23% |
| Q4 2025 | $144.3M | +7.3% |
| Q3 2025 | $141.6M | +2.9% |
| Q2 2025 | $141.2M | +11% |
| Q1 2025 | $130.1M | +6.8% |
| Q4 2024 | $134.5M | +22% |
PRK's revenue has grown year over year for 11 quarters in a row: $177M last quarter, up 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -1.1 points |
| Q2 2026 | 41% | -1.2 points |
| Q1 2026 | 32% | -7 points |
| Q4 2025 | 37% | +1.3 points |
| Q3 2025 | 41% | +7.1 points |
| Q2 2025 | 42% | +3.9 points |
| Q1 2025 | 39% | +4.5 points |
| Q4 2024 | 35% | +8.3 points |
PRK has the edge over MS on profitability, with a higher operating margin.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
PRK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $58.4M | +14% |
| Q2 2026 | $50.5M | +4.4% |
| Q1 2026 | $26.6M | -28% |
| Q4 2025 | $55.7M | +18% |
| Q3 2025 | $51.1M | +21% |
| Q2 2025 | $48.4M | -0.8% |
| Q1 2025 | $36.8M | +17% |
| Q4 2024 | $47.1M | -9.2% |
PRK has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over PRK on shareholder dilution, with a more favorable share count trend.
PRK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1.1K shares |
| 1 year | +12% | +2M shares |
| 3 years | +12% | +2M shares |
| 5 years | +11% | +1.8M shares |
| Available history | +11% | +1.8M shares |
PRK has 18M diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $5.2M |
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
PRK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
| Q2 2026 | -1.8x | Net Cash |
| Q1 2026 | -3.5x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | 0.4x | Very low |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 2.1x | Moderate |
PRK has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
PRK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 13.6 | Oversold |
PRK's weekly RSI is 45 (neutral) and its Stochastic is 14 (oversold).
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS has the edge over PRK on valuation relative to its sector.
PRK PE vs Financial Services Sector
| Metric | PRK | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 13x | 19% above |
| PE % | 56 | 63 | 7 pts below |
PRK is trading at 16x earnings, a 19% premium to the Financial Services sector's median of 13x.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
PRK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $179.0 | 1.5% below |
| 20 week MA | $188.3 | 6.3% below |
| 50 week MA | $175.5 | 0.5% above |
| 100 week MA | $169.0 | 4.4% above |
| 200 week MA | $150.4 | 17% above |
PRK has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 17% above its 200-week average.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.
PRK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $102.8 | $103.2 | +0.4% |
| 2021 | $103.2 | $138.2 | +34% |
| 2022 | $138.2 | $142.6 | +3.2% |
| 2023 | $142.6 | $132.9 | -6.8% |
| 2024 | $132.9 | $174.1 | +31% |
| 2025 | $174.1 | $157.5 | -9.5% |
| 2026 YTD | $157.5 | $176.4 | +12% |
PRK has the edge over MS on returns for 2026, with the stronger performance.